1,3-dihydro-imidazo[4,5-b]quinolin-2-one | 95539-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,3-dihydro-imidazo[4,5-b]quinolin-2-one
• 英文别名: 1,3-Dihydro-imidazo[4,5-b]chinolin-2-on；1,3-Dihydro-imidazo[4,5-b]quinolin-2-one；1,3-dihydroimidazo[4,5-b]quinolin-2-one
• CAS: 95539-36-9
• 化学式: C₁₀H₇N₃O
• 分子量: 185.185
• InChiKey: BINWKEIURMBREF-UHFFFAOYSA-N

物化性质

• 熔点：
  350-354 °C (decomp)
• 密度：
  1.55±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-dihydro-imidazo[4,5-b]quinolin-2-one 在 盐酸 、 tin 、 水 、 硝酸 作用下， 生成 9-amino-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
  参考文献：
  名称：

  Musial, Roczniki Chemii, 1951, vol. 25, p. 46,50,51

  摘要：

  DOI：
• 作为产物：
  描述：

  5-(2-nitro-benzylidene)-imidazolidine-2,4-dione 在 磷化氢 、 氢碘酸 作用下， 生成 1,3-dihydro-imidazo[4,5-b]quinolin-2-one
  参考文献：
  名称：

  Kozak; Musial, Bulletin International de l'Academie Polonaise des Sciences et des Lettres, Classe des Sciences Mathematiques et Naturelles, Serie A: Sciences Mathematiques, 1930, p. 432,435

  摘要：

  DOI：

文献信息

• 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones - inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation
  作者：Nicholas A. Meanwell、Herbert R. Roth、Edward C. R. Smith、Donald L. Wedding、J. J. Kim Wright、J. Stuart Fleming、Elizabeth Gillespie

  DOI：10.1021/jm00113a033

  日期：1991.9

  5-b]quinolin-2-one derivatives was synthesized and evaluated as inhibitors of cAMP hydrolysis by a crude human platelet phosphodiesterase preparation and as inhibitors of ADP- and collagen-induced aggregation of rabbit blood platelets. The parent structure 7a, demonstrated potent inhibitory activity that was enhanced by the introduction of alkyl, alkoxy, or halogen substituents at the 5-, 6-, 7-, and 8-positions

  合成了一系列1,3-二氢-2H-咪唑并[4,5-b]喹啉-2-酮衍生物，并作为粗制人血小板磷酸二酯酶制剂对cAMP水解的抑制剂以及对ADP-和胶原-抑制剂的评估。诱导兔血小板聚集。母体结构7a显示出有效的抑制活性，其通过在5-，6-，7-和8-位上引入烷基，烷氧基或卤素取代基而增强。N-1或N-3处的甲基化产生较弱的cAMP PDE抑制剂和血小板聚集。发现1,3,9,9a-四氢-2H-咪唑并[4,5-b]喹啉-2-酮（6）与它们的完全氧化同类物（7）等价。根据体外的血小板抑制特性，在血栓形成动物模型中预防血栓形成的功效以及良好的血液动力学特征，即1,3-二氢-7，选择8-二甲基-2H-咪唑并[4,5-b]喹啉-2-酮（7o，BMY 20844）进行毒理学评估和临床试验。描述了7o的有效合成。
• Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  申请人：——

  公开号：US20030195194A1

  公开（公告）日：2003-10-16

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: 1 including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF的抑制剂，对治疗各种疾病具有实用性，包括与MIF活性相关的病理条件的治疗。MIF的抑制剂具有以下结构：包括立体异构体、前药和其药用盐，其中n、R1、R2、R3、R4、X、Y和Z如本文所定义。还提供了含有MIF抑制剂的组合物，与药用载体结合，以及使用方法。
• Synthesis of imidazo[1,5-c][1,3]benzodiazepines via an aza-Wittig/carbodiimide-mediated annulation process
  作者：Pedro Molina、Alberto Tárraga、David Curiel、Carmen Ramirez de Arellano

  DOI：10.1016/s0040-4020(97)10050-3

  日期：1997.11

  The first synthesis of the imidazo[1,5-c][1,3]benzodiazepine ring system has been carried out by reaction of the iminophosphorane derived from the (Z)-5-(o-azidoarylidene)hydantoin with isocyanates. The isomeric (E)-tributyliminophosphorane undergoes intramolecular aza Wittig reaction to give the imidazo[4,5-b]quinolin-2-one ring.

  通过衍生自（Z）-5-（邻叠氮基亚芳基）乙内酰脲的亚氨基膦烷与异氰酸酯的反应，进行了咪唑并[1,5-c] [1,3]苯并二氮杂ring环系统的首次合成。异构体（E）-三丁基亚氨基正膦经过分子内的氮杂Wittig反应，得到咪唑并[4，5-b]喹啉-2-酮环。
• Pyrimidine derivatives for labeled binding partners
  申请人：——

  公开号：US20030176677A1

  公开（公告）日：2003-09-18

  Compounds having structure (1) 1 wherein R 1 is —H a protecting group, a linker or a binding partner; and R 2 and R 34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.

  具有结构（1）的化合物，其中R1是- H，保护基，连接剂或结合伙伴；而R2和R3是在规范中定义的。该发明还提供了制备结构（1）化合物的中间体和方法，以及将化合物用作诊断测定中的标记和增强与互补碱基的结合的方法。
• INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
  申请人：Gaeta C.A. Federico

  公开号：US20060194793A1

  公开（公告）日：2006-08-31

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF抑制剂，具有治疗各种疾病的功效，包括治疗与MIF活性相关的病理条件。MIF抑制剂具有以下结构：包括立体异构体，前药和其药学上可接受的盐，其中n，R1，R2，R3，R4，X，Y和Z的定义如本文所述。同时还提供了含有MIF抑制剂和药学上可接受的载体的组合物，以及使用它们的方法。